Results 111 to 120 of about 5,389 (186)

Gyógyítható lesz-e a melanoma? Perspektívák a melanoma kezelésében = Will melanoma be curable? Perspectives in melanoma therapy [PDF]

, 2017
Baltás, Eszter, Gyulai, Rolland, Lengyel, Zsuzsanna   +2 more
core   +1 more source

Precision medicine driven by cancer systems biology [PDF]

, 2017

core   +1 more source

Depletion of γ-glutamylcyclotransferase inhibits breast cancer cell growth via cellular senescence induction mediated by CDK inhibitor upregulation [PDF]

, 2016

core   +1 more source

Growth rate-driven modelling suggests that phenotypic adaptation drives drug resistance in BRAFV600E-mutant melanoma. [PDF]

Commun Biol
Hamis S, Browning AP, Jenner AL, Villa C, Maini PK, Cassidy T.   +5 more
europepmc   +1 more source

Encorafenib overdose [PDF]

Reactions Weekly, 2021
openaire   +1 more source

Updated result from the phase 2 PHAROS study: has the sustained efficacy and tolerability of encorafenib plus binimetinib been demonstrated in patients with <i>BRAF</i> V600E-mutant metastatic non-small-cell lung cancer? [PDF]

J Thorac Dis
Yonesaka K.
europepmc   +1 more source

Cost-effectiveness of first-line encorafenib plus cetuximab with mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer. [PDF]

iScience
Shu Y, Shi F, Xiong J, Zheng J, Ding Y, Zhang W, Xu P, Zhang Q.   +7 more
europepmc   +1 more source

Sweet syndrome in a patient receiving encorafenib and binimetinib therapy for malignant melanoma

JAAD Case Reports
Myiah Quach, BS, John P. Antonelli, BS, Charlotte LaSenna, MD, Mackenzie Asel, MD, Jennifer Pleva, DNP, Vincent T. Ma, MD   +5 more
doaj   +1 more source

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series. [PDF]

Front Endocrinol (Lausanne)
Yamin T, Cohen O, Robenshtok E, Izkhakov E, Miodovnik M, Gutfeld O, Leshem Y, Meirovitz R, Warshavsky A, Muhanna N, Finkel I.   +10 more
europepmc   +1 more source

BREAKWATER Phase III: results for encorafenib and cetuximab plus mFOLFOX6 in first-line <i>BRAF</i> V600E-mutant metastatic colorectal cancer. [PDF]

Future Oncol
Kopetz S, Tabernero J, Élez E.
europepmc   +1 more source